LCD L36139: MolDX: Biomarkers in Cardiovascular Risk Assessment — CGS

Eliquis (apixaban) is an oral anticoagulant approved as a tablet (including a tablet for suspension formulation), which routes it through Medicare Part D for outpatient prescription coverage. As an or

Eliquis (apixaban) has received approval for a new oral suspension dosage form under NDA220073, expanding access for patients unable to swallow tablets—likely pediatric or dysphagic populations. As an

Argatroban in sodium chloride is an injectable medication that will likely receive a J-code for billing purposes under Medicare Part B. As an intravenous drug, it may also qualify for pass-through pay

This final LCD from Noridian (JE/JF) governs coverage of temporary nontherapeutic ambulatory cardiac monitoring devices across 15 western states, effective June 21, 2026. It defines coverage criteria